Skye Bioscience announced the failure of its obesity drug nimacimab—an antibody targeting cannabinoid receptor 1 (CB1)—to achieve significant weight loss in a phase 2 trial. Nimacimab monotherapy led to only a 1.5% weight reduction, barely surpassing placebo, while its combination with semaglutide showed an additional 13.2% weight loss. Lower-than-expected drug exposure was cited as a potential limitation, prompting plans to explore higher doses. Shares plummeted over 60% in premarket trading following the release. This setback extends challenges faced by CB1 inhibitors in obesity treatment development.